Evidence map›Paper›PMID 31847126›Full record

ArticleInternational journal of molecular sciences2019

O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension.

Jarrod W Barnes, Liping Tian, Stefanie Krick, E Scott Helton, Rebecca S Denson, Suzy A A Comhair, Raed A Dweik

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. O-GlcNAc regulates anti-fibrotic genes in lung fibroblasts through EZH2.Journal of cellular and molecular medicine · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. The Role of Glutamine and Glutaminase in Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2022
    Review
  16. Review
  17. Journal of thoracic disease · 2021
    Article
  18. Article
  19. P53 in the impaired lungs.DNA repair · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jarrod W BarnesDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, THT 422, 1720 2nd Ave S, Birmingham, AL 35294-0006, USA.
Liping TianDepartment of Inflammation & Immunity, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Stefanie KrickDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, THT 422, 1720 2nd Ave S, Birmingham, AL 35294-0006, USA.
E Scott HeltonDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, THT 422, 1720 2nd Ave S, Birmingham, AL 35294-0006, USA.
Rebecca S DensonDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, THT 422, 1720 2nd Ave S, Birmingham, AL 35294-0006, USA.
Suzy A A ComhairDepartment of Inflammation & Immunity, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Raed A DweikDepartment of Inflammation & Immunity, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
University of Alabama at Birmingham · USCleveland Clinic · US

Funding

Mechanisms of metabolic dysregulation in pulmonary hypertensionR01HL130209 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI DWEIK, RAED A. · 2016 to 2020
$2.9M
Metabolic drivers and sensors of cell proliferation in pulmonary hypertensionR00HL131866 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARNES, JARROD W. · 2018 to 2020
$731k
NHLBI NIH HHS R00 HL131866NHLBI NIH HHS R00HL131866NHLBI NIH HHS R01 HL130209NHLBI NIH HHS R01HL130209
6 · The paper itself

Abstract

Idiopathic pulmonary arterial hypertension (IPAH) is considered a vasculopathy characterized by elevated pulmonary vascular resistance due to vasoconstriction and/or lung remodeling such as plexiform lesions, the hallmark of the PAH, as well as cell proliferation and vascular and angiogenic dysfunction. The serine/threonine hydroxyl-linked N-Acetylglucosamine (O-GlcNAc) transferase (OGT) has been shown to drive pulmonary arterial smooth muscle cell (PASMC) proliferation in IPAH. OGT is a cellular nutrient sensor that is essential in maintaining proper cell function through the regulation of cell signaling, proliferation, and metabolism. The aim of this study was to determine the role of OGT and O-GlcNAc in vascular and angiogenic dysfunction in IPAH. Primary isolated human control and IPAH patient PASMCs and pulmonary arterial endothelial cells (PAECs) were grown in the presence or absence of OGT inhibitors and subjected to biochemical assessments in monolayer cultures and tube formation assays, in vitro vascular sprouting 3D spheroid co-culture models, and de novo vascularization models in NODSCID mice. We showed that knockdown of OGT resulted in reduced vascular endothelial growth factor (VEGF) expression in IPAH primary isolated vascular cells. In addition, specificity protein 1 (SP1), a known stimulator of VEGF expression, was shown to have higher O-GlcNAc levels in IPAH compared to control at physiological (5 mM) and high (25 mM) glucose concentrations, and knockdown resulted in decreased VEGF protein levels. Furthermore, human IPAH PAECs demonstrated a significantly higher degree of capillary tube-like structures and increased length compared to control PAECs. Addition of an OGT inhibitor, OSMI-1, significantly reduced the number of tube-like structures and tube length similar to control levels. Assessment of vascular sprouting from an in vitro 3D spheroid co-culture model using IPAH and control PAEC/PASMCs and an in vivo vascularization model using control and PAEC-embedded collagen implants demonstrated higher vascularization in IPAH compared to control. Blocking OGT activity in these experiments, however, altered the vascular sprouting and de novo vascularization in IPAH similar to control levels when compared to controls. Our findings in this report are the first to describe a role for the OGT/O-GlcNAc axis in modulating VEGF expression and vascularization in IPAH. These findings provide greater insight into the potential role that altered glucose uptake and metabolism may have on the angiogenic process and the development of plexiform lesions. Therefore, we believe that the OGT/O-GlcNAc axis may be a potential therapeutic target for treating the angiogenic dysregulation that is present in IPAH.

Indexed as

AdultAnimalsCoculture TechniquesEnzyme InhibitorsFamilial Primary Pulmonary HypertensionFemaleGene Expression RegulationHumansMaleMiceMice, Inbred NODMice, SCIDMiddle AgedN-AcetylglucosaminyltransferasesNeovascularization, PathologicVascular Endothelial Growth Factor AEnzyme InhibitorsN-AcetylglucosaminyltransferasesO-GlcNAc transferaseVascular Endothelial Growth Factor AVEGFA protein, humanangiogenesisIPAHO-GlcNAcOGTVEGF

Identifiers

PMID31847126
PMCPMC6941156
OpenAlexW2995245904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.